Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease. Our computational approach to polypharmacology is unique in the industry. Screening for actives with target-specific black boxes has limited upside. Instead, we use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously. We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics. Not all hits are created equal. Our commitment to collaborating holistically improves the odds of reaching milestones dramatically. For our large biotech and pharma customers, we help enrich existing portfolios, building custom models that deliver IP-grade, proprietary insights with breakthrough efficiency and precision. Separately, across a portfolio of more than 50 joint ventures and growing, we work at the vanguard of a wide variety of therapeutic areas to help get new medicines to patients faster and more precisely. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com Cyclica. From molecule to medicine.Something looks off?